Drug-induced removal of nitrogen derivatives in urine: A new concept whose time has come

Hepatology

Volumn 59, Issue 3, 2014, Pages 764-766

  Córdoba, Juan ^a   Ventura Cots, Meritxell ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; CYTOKINE; GLYCEROL PHENYLBUTYRATE; LACTITOL; LACTULOSE; NEOMYCIN; NITROGEN DERIVATIVE; ORNITHINE PHENYLACETATE; TOLL LIKE RECEPTOR;

ALCOHOL LIVER CIRRHOSIS; AMMONIA BLOOD LEVEL; CONSTIPATION; DECOMPENSATED LIVER CIRRHOSIS; DEHYDRATION; EDITORIAL; EXPOSURE; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HOSPITAL ADMISSION; HUMAN; HYPERAMMONEMIA; HYPONATREMIA; INTESTINE FLORA; LIVER CIRRHOSIS; LIVER FUNCTION; NERVOUS SYSTEM INFLAMMATION; NITROSATIVE STRESS; ORGANOLEPTIC PROPERTY; PATHOGENESIS; PRIORITY JOURNAL; RECURRENT DISEASE; UREA CYCLE DISORDER; URINE;

AMMONIA; FEMALE; GLYCEROL; HEPATIC ENCEPHALOPATHY; HUMANS; HYPERAMMONEMIA; MALE; PHENYLBUTYRATES;

EID: 84896734003     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26789     Document Type: Editorial

References (15)

1. Cordoba J. New assessment of hepatic encephalopathy. J Hepatol 2011;54:1030-1040.
2. Stepanova M, Mishra A, Venkatesan C, Younossi ZM. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol 2012;10:1034-1041.
3. Strauss E, da Costa MF. The importance of bacterial infections as precipating factors of chronic hepatic encephalopathy in cirrhosis. Hepatogastroenterology 1998;45:900-904.
4. Rose CF. Ammonia-lowering strategies for the treatment of hepatic encephalopathy. Clin Pharmacol Ther 2012;92:321-331.
5. Häussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008;57:1156-1165.
6. Shawcross DL, Olde Damink SW, Butterworth RF, Jalan R. Ammonia and hepatic encephalopathy: the more things change, the more they remain the same. Metab Brain Dis 2005;20:169-179.
7. Butterworth RF. Complications of cirrhosis III. Hepatic encephalopathy. J Hepatol 2000;32(1 Suppl):171-180.
8. Garcia-Martinez R, Rovira A, Alonso J, Jacas C, Simón-Talero M, Chavarria L, et al. Hepatic encephalopathy is associated with post-transplant cognitive function and brain volume. Liver Transpl 2011;17:38-46.
9. Maestri NE, Brusilow SW, Clissold DB, Bassett S. Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 1996;335:855-859.
10. Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS, Jr., Alexeeva O, et al.; HALT-HE Study Group. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology 2014;59:1073-1083.
11. Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009;137:885-889.
12. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362:1071-1081.
13. Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Dai ta K, White MB, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 2012;303:G675-G678.
14. Ventura-Cots M, Arranz JA, Simón-Talero M, Torrens M, Blanco A, Riudor E, et al. Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study. J Clin Gastroenterol 2013 Jun 6. doi: 10.1097/MCG.0b013e318299c789.
15. Laleman W, Simon-Talero M, Maleux G, Perez M, Ameloot K, Soriano G, Villalba J, et al.; EASL-CLIF-Consortium. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology 2013;57:2448-2457.